Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17441018 | 1.00 | GPR3 (0.41) | GPR3 | |
| SCHEMBL19428099 | 1.00 | GPR3 (0.41) | GPR3 | |
| SCHEMBL17440745 | 0.95 | GPR3 (0.41) | GPR3 | |
| SCHEMBL17440743 | 0.95 | GPR3 (0.41) | GPR3 | |
| SCHEMBL8152542 | 0.93 | GPR3 (0.39) | GPR3 | |
| SCHEMBL15357241 | 0.80 | GPR3 (0.37) | GPR3 | |
| SCHEMBL31091548 | 0.80 | GPR3 (0.37) | GPR3 | |
| SCHEMBL8281426 | 0.80 | GPR3 (0.37) | GPR3 | |
| SCHEMBL1515549 | 0.79 | GPR3 (0.39) | GPR3 | |
| SCHEMBL2449573 | 0.79 | GPR3 (0.39) | GPR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138987-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CONTINEUM THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-12565494-B2 | Inhibitors of human respiratory syncytial virus and metapneumovirus | MERCK SHARP & DOHME LLC | 2026-03-03 | — | — | US | disclosed |
| US-12565501-B2 | Muscarinic acetylcholine M1 receptor antagonists | CONTINEUM THERAPEUTICS, INC. (US) | 2026-03-03 | — | — | US | disclosed |
| US-12410179-B2 | Modulators of TNF alpha activity and uses thereof | RAYTHERA, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| US-20250263418-A1 | MODULATORS OF TNF ALPHA ACTIVITY AND USES THEREOF | RAYTHERA, INC. | 2025-08-21 | — | — | US | disclosed |
| WO-2025137267-A1 | MODULATORS OF TNF-ALPHA ACTIVITY | FORWARD THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| EP-4568948-A1 | COMPOUNDS FOR TREATING CANCER | Genesis Therapeutics, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| US-20250171455-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CONTINEUM THERAPEUTICS INC (US) | 2025-05-29 | — | — | US | disclosed |
| US-20250127795-A1 | Fused Pentacyclic Imidazole Derivatives as Modulators of TNF Activity | UCB Biopharma SRL (BE) | 2025-04-24 | — | — | US | disclosed |
| EP-4522604-A1 | INHIBITORS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS AND METAPNEUMOVIRUS | Merck Sharp & Dohme LLC (US) | 2025-03-19 | — | — | EP | disclosed |
| US-20130303508-A1 | NAMPT INHIBITORS | ABBVIE INC. (US) | 2013-11-14 | — | — | US | disclosed |
| US-20130303511-A1 | NAMPT INHIBITORS | ABBVIE INC. (US) | 2013-11-14 | — | — | US | disclosed |
| US-8551984-B2 | Aminopyrimidines as SYK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-10-08 | — | — | US | disclosed |
| US-20130053386-A1 | DIARYL ETHER DERIVATIVES AS NOTCH SPARING GAMMA SECRETASE INHIBITORS | MERCK SHARP & DOHME LLC | 2013-02-28 | — | — | US | disclosed |
| US-20130053386-A1 | DIARYL ETHER DERIVATIVES AS NOTCH SPARING GAMMA SECRETASE INHIBITORS | MERCK SHARP & DOHME LLC | 2013-02-28 | — | — | US | disclosed |
| US-20130053386-A1 | DIARYL ETHER DERIVATIVES AS NOTCH SPARING GAMMA SECRETASE INHIBITORS | MERCK SHARP & DOHME LLC | 2013-02-28 | — | — | US | disclosed |
| US-20120277192-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME LLC | 2012-11-01 | — | — | US | disclosed |
| US-20110245205-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME LLC | 2011-10-06 | — | — | US | disclosed |
| WO-2011075517-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-06-23 | — | — | WO | disclosed |
| WO-2011046774-A1 | DIARYL ETHER DERIVATIVES AS NOTCH SPARING GAMMA SECRETASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12410179-B2 | Modulators of TNF alpha activity and uses thereof | TNF, TNFRSF1A, TNFRSF9 | GPR3 4463/4885 |
| US-20110245205-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | SYK, BTK, LCK | GPR3 2255/4885 |
| US-20130303508-A1 | NAMPT INHIBITORS | NAMPT, NNMT, NAPRT | GPR3 3922/4885 |
| US-20130303511-A1 | NAMPT INHIBITORS | NAMPT, NNMT, NAPRT | GPR3 3922/4885 |
| US-12565501-B2 | Muscarinic acetylcholine M1 receptor antagonists | CHRM1, CHRM2, CHRM3 | GPR3 67/4885 |
| US-20260138987-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CHRM1, CHRM5, CHRM3 | GPR3 62/4885 |
| US-20130053386-A1 | DIARYL ETHER DERIVATIVES AS NOTCH SPARING GAMMA SECRETASE INHIBITORS | BACE1, BACE2, GSAP | GPR3 619/4885 |
| US-20250127795-A1 | Fused Pentacyclic Imidazole Derivatives as Modulators of TNF Activity | TNF, TNFRSF1A, NFKBIA | GPR3 2133/4885 |
| US-12565494-B2 | Inhibitors of human respiratory syncytial virus and metapneumovirus | NHERF1, ZC3HAV1, SARS1 | GPR3 1672/4885 |
| US-20250263418-A1 | MODULATORS OF TNF ALPHA ACTIVITY AND USES THEREOF | TNF, TNFRSF1A, TNFRSF9 | GPR3 4463/4885 |
| US-20250171455-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CHRM1, CHRM2, CHRM3 | GPR3 147/4885 |
| US-20120277192-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | SYK, BTK, LCK | GPR3 2255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.